查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1858787

Iloprost類藥物：全球市場佔有率和排名、總銷售額和需求預測（2025-2031 年）

Iloprost Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 74 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球Iloprost藥物市場規模預計為 6,234 萬美元，預計到 2031 年將萎縮至 4,498 萬美元，2025 年至 2031 年的複合年成長率為 -4.6%。

Iloprost是一種用於治療血管收縮、組織血流受限疾病的藥物，例如肺動脈高壓（PAH）、硬皮症和雷諾氏現象。 2024年，Iloprost的全球產量約為104萬單位，全球平均市場價格約為每單位60美元。

近年來，肺動脈高壓（PAH）及相關血管疾病已成為許多國家和地區的公共衛生重點，各國政府和監管機構更新了臨床指南，以提高診斷率和早期療育。這為Iloprost的廣泛應用奠定了製度基礎。尤其值得一提的是，美國FDA核准Iloprost素注射液（Auramin）用於治療嚴重凍傷，並認可其可降低截肢風險，這標誌著伊洛前列素的應用範圍超越了傳統的PAH適應症，極大地增強了製藥公司和投資者對這一新興治療領域潛力的信心。此外，醫療服務提供者日益重視改善微循環和降低血管阻力以改善患者預後，加之患者和臨床醫生對慢性維持治療和急性介入治療的需求不斷成長，這些因素共同推動了給藥方式（吸入、靜脈注射）和器械便捷性的創新。學名藥的上市以及某些地區的生命週期管理也有助於降低成本並擴大用藥範圍。

儘管Iloprost具有很高的成長潛力，但它也面臨一些限制。治療費用相對較高，尤其是在需要使用專用吸入或霧化裝置、輸注系統或住院給藥的情況下。各國的保險覆蓋範圍和報銷政策差異很大，這可能會限制其廣泛應用和普及。副作用和耐受性問題（例如低血壓、臉部潮紅、咳嗽和氣道刺激以及頭痛）需要密切的臨床監測和劑量調整，這可能會降低用藥的便利性和患者的依從性。新適應症的核准流程可能很漫長，並且需要強力的臨床證據來證明其在新用途的安全性和有效性。同時，專利到期和學名藥的競爭威脅著現有品牌產品的利潤率。此外，基礎設施負擔——包括設備、給藥系統、分銷和物流以及必要的低溫運輸——也構成挑戰，尤其是在新興市場和資源匱乏的市場。

從臨床和患者的觀點來看，對Iloprost的需求正朝著更多樣化、個體化和便利的方向發展。醫生和患者越來越期望Iloprost能夠用於慢性疾病管理（例如肺動脈高壓）和急性治療（例如凍傷和血管損傷），並能快速起效，顯著改善患者的生活品質。改良的吸入製劑——更小巧、更便攜的霧化器、更少的每日劑量以及更易於使用的吸入系統——正成為強勁的需求促進因素。平衡患者依從性和長期療效變得日益重要。臨床醫生越來越關注伊洛前列素與其他肺動脈高壓藥物聯合治療以及作為缺血性和循環衰竭的輔助/輔助性治療的潛在用途。在新興市場，不斷擴大的公共保險和醫療保健體系顯著增加了對經濟有效的Iloprost產品和學名藥藥的需求。同時，人們也越來越期待該藥物能核准用於治療凍傷、血管性皮膚病和微循環障礙等新適應症，並進行相應的臨床試驗。

上游原料和生產流程對Iloprost的品質、成本和供應穩定性有著深遠的影響。Iloprost的合成需要高純度的有機化學中間體，這些中間體含有雙環結構、不飽和碳鏈、羥基和烯烴官能基以及特定的前列腺環素樣結構。必須嚴格控制立體化學和雜質譜（包括異構體、殘留金屬催化劑和溶劑殘留）。此外，吸入或靜脈注射製劑需要高純度且符合藥典/GMP標準的添加劑、溶劑、緩衝系統和穩定劑。關鍵催化劑、金屬錯合、精細化學中間體和溶劑的供應可能受到原料短缺、環境法規（特別是對有機溶劑排放和廢棄物處理的要求）、進出口限制以及供應商資質要求的限制。吸入裝置中使用的材料（例如塑膠零件、霧化器頭、過濾器）及其環境穩定性也會影響生產投資和整體成本結構。該產品的毛利率約為80%。

本報告旨在按地區/國家、類型和應用對全球Iloprost藥物市場進行全面分析，重點關注總銷售額、市場佔有率和主要企業的排名。

Iloprost藥物市場規模、估算和預測均以銷售收入為指標，以2024年為基準年，並包含2020年至2031年的歷史數據和預測數據。我們運用定量和定性分析，幫助讀者制定業務/成長策略，評估市場競爭格局，分析公司在當前市場中的地位，並就Iloprost藥物做出明智的商業決策。

市場區隔

公司

  • Actelion（J & J）
  • Bayer AG
  • Teva
  • Eastpharma
  • Zentiva

按類型分類的細分市場

  • 吸入
  • 靜脈

應用領域

  • 醫院
  • 診所

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Iloprost Drugs was estimated to be worth US$ 62.34 million in 2024 and is forecast to a readjusted size of US$ 44.98 million by 2031 with a CAGR of -4.6% during the forecast period 2025-2031.

Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues.In 2024, global Iloprost drug production reached approximately 1.04 m units, with an average global market price of around US$ 60 per unit.

In recent years, pulmonary arterial hypertension (PAH) and related vascular diseases have been designated as public health priorities in many countries and regions, with governmental and regulatory bodies updating clinical guidelines to improve diagnosis rates and early intervention. This creates institutional channels for broader adoption of Iloprost. Notably, the US FDA's approval of Iloprost injection (Aurlumyn) for severe frostbite to reduce the risk of amputation marks a landmark extension beyond traditional PAH indications, boosting confidence among pharmaceutical companies and investors in its potential in new therapeutic areas. In addition, healthcare providers' increased emphasis on improving microcirculation and reducing vascular resistance to enhance patient outcomes, together with rising demand from patients and clinicians for both chronic maintenance and acute intervention therapies, propel innovation in delivery modes (inhalation, intravenous) and device convenience. Generic entry and lifecycle management in some jurisdictions also contribute to cost reduction and increased access.

Even with strong growth potential, Iloprost faces several constraints. The cost of treatment is relatively high, especially when specialized inhalation or nebulization devices, infusion systems, or hospital-based administration are required; insurance or reimbursement coverage varies widely between countries, which may hinder uptake and accessibility. The side effect profile and tolerability issues (hypotension, flushing, cough or airway irritation, headache, etc.) require careful clinical monitoring and dosing adjustments, which may reduce convenience and patient compliance. Regulatory pathways for new indications can be lengthy, and demonstrating safety and efficacy in novel applications demands robust clinical evidence; meanwhile, patent expirations and generic competition pose threats to established branded products' margins. Also, the infrastructure burden-devices, delivery systems, distribution/logistics, cold chain where applicable-pose challenges, especially in emerging or low-resource markets.

Clinically and from the patient perspective, demand for Iloprost is moving toward greater diversity, personalization, and convenience. Physicians and patients increasingly expect Iloprost to address both chronic management (such as in PAH) and acute interventions (such as frostbite or vascular injury), with rapid onset of action and measurable improvements in life quality. Improvements in inhaled formulations-smaller, more portable nebulizers, fewer daily doses, better user-friendly inhaler systems-are emerging as strong demand points. Patient adherence vs long-term efficacy balance is of growing importance. Clinician interest in combination therapies with other PAH agents, or exploring supportive/adjuvant use in ischemic or circulatory-deficit conditions, is increasing. In emerging markets, as public insurance / health systems expand, demand for cost-effective versions or generic Iloprost increases significantly. Concurrently, there is rising anticipation for regulatory recognition of new indications and supportive clinical trials in frostbite, vascular skin disorders, and microcirculation-related conditions.

The upstream raw materials and manufacturing processes deeply affect Iloprost's quality, cost, and supply stability. Synthesis of Iloprost involves high-purity organic chemical intermediates encompassing bicyclic ring systems, unsaturated carbon chains, hydroxyl and alkene functional groups, and the specific prostacyclin-analogous framework, requiring strict control of stereochemistry and impurity profile (including isomers, residual metal catalysts, solvent residues, etc.). Moreover, formulations for inhaled or intravenous use demand excipients, solvents, buffer systems, stabilizers that meet high purity and pharmacopeial / GMP standards. Key catalysts, metal complexes, fine chemical intermediates and solvents may be limited by raw material scarcity, environmental regulation (especially organic solvent emissions and waste disposal), import/export controls, and supplier qualification and certification requirements. The materials used in inhalation devices (plastic components, nebulizer heads, filters, etc.) and their environmental stability also affect production investment and overall cost structure.The gross profit margin of this product is around 80%.

This report aims to provide a comprehensive presentation of the global market for Iloprost Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Iloprost Drugs by region & country, by Type, and by Application.

The Iloprost Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iloprost Drugs.

Market Segmentation

By Company

  • Actelion (J & J)
  • Bayer AG
  • Teva
  • Eastpharma
  • Zentiva

Segment by Type

  • Inhaled
  • Intravenous

Segment by Application

  • Hospital
  • Clinic

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Iloprost Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Iloprost Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Iloprost Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Iloprost Drugs Product Introduction
  • 1.2 Global Iloprost Drugs Market Size Forecast (2020-2031)
  • 1.3 Iloprost Drugs Market Trends & Drivers
    • 1.3.1 Iloprost Drugs Industry Trends
    • 1.3.2 Iloprost Drugs Market Drivers & Opportunity
    • 1.3.3 Iloprost Drugs Market Challenges
    • 1.3.4 Iloprost Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Iloprost Drugs Players Revenue Ranking (2024)
  • 2.2 Global Iloprost Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies Iloprost Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Iloprost Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Iloprost Drugs
  • 2.6 Iloprost Drugs Market Competitive Analysis
    • 2.6.1 Iloprost Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Iloprost Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Iloprost Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Inhaled
    • 3.1.2 Intravenous
  • 3.2 Global Iloprost Drugs Sales Value by Type
    • 3.2.1 Global Iloprost Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Iloprost Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Iloprost Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Clinic
  • 4.2 Global Iloprost Drugs Sales Value by Application
    • 4.2.1 Global Iloprost Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Iloprost Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global Iloprost Drugs Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Iloprost Drugs Sales Value by Region
    • 5.1.1 Global Iloprost Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Iloprost Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Iloprost Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Iloprost Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Iloprost Drugs Sales Value, 2020-2031
    • 5.2.2 North America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Iloprost Drugs Sales Value, 2020-2031
    • 5.3.2 Europe Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Iloprost Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Iloprost Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Iloprost Drugs Sales Value, 2020-2031
    • 5.5.2 South America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Iloprost Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Iloprost Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Iloprost Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Iloprost Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Iloprost Drugs Sales Value, 2020-2031
    • 6.3.2 United States Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Iloprost Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Iloprost Drugs Sales Value, 2020-2031
    • 6.5.2 China Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Iloprost Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Iloprost Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Iloprost Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Iloprost Drugs Sales Value, 2020-2031
    • 6.9.2 India Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Iloprost Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Actelion (J & J)
    • 7.1.1 Actelion (J & J) Profile
    • 7.1.2 Actelion (J & J) Main Business
    • 7.1.3 Actelion (J & J) Iloprost Drugs Products, Services and Solutions
    • 7.1.4 Actelion (J & J) Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Actelion (J & J) Recent Developments
  • 7.2 Bayer AG
    • 7.2.1 Bayer AG Profile
    • 7.2.2 Bayer AG Main Business
    • 7.2.3 Bayer AG Iloprost Drugs Products, Services and Solutions
    • 7.2.4 Bayer AG Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Bayer AG Recent Developments
  • 7.3 Teva
    • 7.3.1 Teva Profile
    • 7.3.2 Teva Main Business
    • 7.3.3 Teva Iloprost Drugs Products, Services and Solutions
    • 7.3.4 Teva Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Teva Recent Developments
  • 7.4 Eastpharma
    • 7.4.1 Eastpharma Profile
    • 7.4.2 Eastpharma Main Business
    • 7.4.3 Eastpharma Iloprost Drugs Products, Services and Solutions
    • 7.4.4 Eastpharma Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Eastpharma Recent Developments
  • 7.5 Zentiva
    • 7.5.1 Zentiva Profile
    • 7.5.2 Zentiva Main Business
    • 7.5.3 Zentiva Iloprost Drugs Products, Services and Solutions
    • 7.5.4 Zentiva Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Zentiva Recent Developments

8 Industry Chain Analysis

  • 8.1 Iloprost Drugs Industrial Chain
  • 8.2 Iloprost Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Iloprost Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Iloprost Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Iloprost Drugs Market Trends
  • Table 2. Iloprost Drugs Market Drivers & Opportunity
  • Table 3. Iloprost Drugs Market Challenges
  • Table 4. Iloprost Drugs Market Restraints
  • Table 5. Global Iloprost Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Iloprost Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Iloprost Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Iloprost Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Iloprost Drugs
  • Table 10. Global Iloprost Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Iloprost Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Iloprost Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Iloprost Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Iloprost Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Iloprost Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Iloprost Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Iloprost Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Iloprost Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Iloprost Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Iloprost Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Iloprost Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Iloprost Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Iloprost Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Iloprost Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Iloprost Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Iloprost Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Iloprost Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Iloprost Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Iloprost Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Actelion (J & J) Basic Information List
  • Table 32. Actelion (J & J) Description and Business Overview
  • Table 33. Actelion (J & J) Iloprost Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Iloprost Drugs Business of Actelion (J & J) (2020-2025)
  • Table 35. Actelion (J & J) Recent Developments
  • Table 36. Bayer AG Basic Information List
  • Table 37. Bayer AG Description and Business Overview
  • Table 38. Bayer AG Iloprost Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Iloprost Drugs Business of Bayer AG (2020-2025)
  • Table 40. Bayer AG Recent Developments
  • Table 41. Teva Basic Information List
  • Table 42. Teva Description and Business Overview
  • Table 43. Teva Iloprost Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Iloprost Drugs Business of Teva (2020-2025)
  • Table 45. Teva Recent Developments
  • Table 46. Eastpharma Basic Information List
  • Table 47. Eastpharma Description and Business Overview
  • Table 48. Eastpharma Iloprost Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Iloprost Drugs Business of Eastpharma (2020-2025)
  • Table 50. Eastpharma Recent Developments
  • Table 51. Zentiva Basic Information List
  • Table 52. Zentiva Description and Business Overview
  • Table 53. Zentiva Iloprost Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Iloprost Drugs Business of Zentiva (2020-2025)
  • Table 55. Zentiva Recent Developments
  • Table 56. Key Raw Materials Lists
  • Table 57. Raw Materials Key Suppliers Lists
  • Table 58. Iloprost Drugs Downstream Customers
  • Table 59. Iloprost Drugs Distributors List
  • Table 60. Research Programs/Design for This Report
  • Table 61. Key Data Information from Secondary Sources
  • Table 62. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Iloprost Drugs Product Picture
  • Figure 2. Global Iloprost Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Iloprost Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Iloprost Drugs Report Years Considered
  • Figure 5. Global Iloprost Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Iloprost Drugs Revenue in 2024
  • Figure 7. Iloprost Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Inhaled Picture
  • Figure 9. Intravenous Picture
  • Figure 10. Global Iloprost Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Iloprost Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Hospital
  • Figure 13. Product Picture of Clinic
  • Figure 14. Global Iloprost Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Iloprost Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America Iloprost Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Iloprost Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Iloprost Drugs Sales Value (%), (2020-2031)
  • Figure 27. United States Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Iloprost Drugs Industrial Chain
  • Figure 49. Iloprost Drugs Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed